Dren Bio

B-cells in multiple myeloma
#Acquisition #Bispecific Antibodies #Dren Bio #Finance #Immunology #Sanofi

Bi-specific antibody acquisition broadens immunology pipeline

Sanofi and Dren Bio, a clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that… Read More

#Business & Investment #News